The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Novel methods to assess the effectiveness of chemotherapy in AML patients: MRD
It is extremely important to assess the long-term effects of chemotherapy in patients with acute myeloid leukemia (AML); however, with the knowledge of minimal residual disease, it is understood that not all malignant clones can be seen under the microscope. In this interview, Felicitas Thol, MD, of Hannover Medical School, Hannover, Germany, discusses the importance of using novel techniques when observing remission in patients. Although challenging compared to other diseases, such as chronic myeloid leukemia (CML), Dr Thol suggests a more individualized and sensitive approach should be taken due to the complex nature of AML. This interview was held at the American Society of Hematology (ASH) Annual Meeting 2017 in Atlanta, GA.
